摘要
目的:探讨骨桥蛋白(OPN)作为卵巢上皮癌肿瘤标志物及联合检测CA125对卵巢上皮癌的临床诊断、病情监测的价值。方法:采集卵巢上皮癌患者40例、卵巢上皮类良性肿瘤患者48例及健康妇女48例的血清样品,分别用ELISA法及微粒子化学发光法测定OPN和CA125含量。结果:与良性肿瘤组和健康妇女组相比,卵巢上皮癌患者血清OPN和CA125的含量明显升高。OPN检测敏感度、特异度分别为82·5%、93·8%,CA125检测敏感度、特异度分别为72·5%、89·6%,联合检测敏感度92·5%。卵巢上皮癌患者术前血清OPN和CA125明显高于术后,Ⅲ期卵巢癌患者的OPN和CA125明显高于Ⅰ、Ⅱ期。结论:OPN是一种较理想的卵巢上皮癌肿瘤标志物,其血清水平可作为卵巢上皮癌诊断和病情监测的临床指标,联合CA125检测可提高其临床应用价值。
Objective： To investigate the clinical value of osteopontin （OPN） as a tumor marker and combined detection of the serum levels of OPN and CA125 in diagnosing and monitoring of epithelium ovarian cancer. Methods： Serum levels of OPN and CA125 in 40 patients with epithelium ovarian cancer,48 patients with epithelium benign ovarian tumor and 48 normal women as control group were measured by ELISA and chemiluminescent microparticle immunoassay technology. Results： The levels of OPN and CA125 in epithelium ovarian cancer were significantly higher than those in benign ovarian tumor and control group. The sensitivity and the specificity of OPN were 82.5% and 93.8%, respectively. The sensitivity and the specificity of CA125 were 72.5% and 89.6%, respectively. The sensitivity of combined detection of two markers was 92.5%. Both serum OPN and CA125 levels of the preoperative epithelium ovarian cancer were higher than those of the postoperative epithelium ovarian cancer. The OPN and CA125 levels of epithelium ovarian cancer stage Ⅲ were .higher than those of stage Ⅰ and Ⅱ. Conclusion ： OPN is an ideal tumor marker and it can be used in diagnosing and monitoring of epithelium ovarian cancer. The clinical value can be increased by combined use of OPN and CA125.
出处
《中国计划生育学杂志》
北大核心
2007年第5期303-305,共3页
Chinese Journal of Family Planning
基金
河北省科技厅科技攻关项目(No.062761191)
